ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

DCE Board Recompetition Concepts

July 17, 1987

In Brief: CREG To Be Used In Viral Oncology, Nutrition, Cell Kinetics, Immunology, Rauscher Tells NCAB

April 4, 1975

Neutron Therapy “Treatment Of Choice” In Salivary Gland Tumors – 100 Percent Complete Reponses

June 13, 1986

Joe Gray Moves To OHSU Knight Cancer Institute

January 21, 2011

NIH Revises Application Receipt Dates

November 22, 1985

Taxol Plus Carboplatin Increased Survival Of NSCLC In Patients 70 And Older

June 25, 2010